Clinical trial
A Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement…
NCT02432144 · Ultragenyx Pharmaceutical Inc, Industry · Completed
Key facts
| NCT number | NCT02432144 |
|---|---|
| Title | A Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Therapy in Subjects With Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7) |
| Official title | A Long-Term Open-Label Treatment and Extension Study of UX003 rhGUS Enzyme Replacement Therapy in Subjects With MPS 7 |
| Lead sponsor | Ultragenyx Pharmaceutical Inc, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Sly Syndrome, MPS VII, Mucopolysaccharidosis, Mucopolysaccharidosis VII |
| Intervention type | Drug |
| Interventions | UX003 |
| Enrollment | 12 |
| Start date | Nov 10, 2015 |
| Primary completion | Jan 14, 2019 |
| Completion | Jan 14, 2019 |
| First posted | May 1, 2015 |
| Last update posted | Jul 30, 2020 |
| Countries | Brazil, Mexico, Portugal, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: